MedTrace Logo

huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer

NCT05057715 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2025-06-25

No results posted yet for this study

Summary

This is a Phase I study evaluating the safety and feasibility of lentiviral transduced huCART-meso cells when given in combination with VCN-01 in a 3+3 dose (de)escalation design.

Conditions

Interventions

BIOLOGICAL

VCN-01

Intravenous administration of VCN-01

BIOLOGICAL

huCART-meso Cells

Intravenous administration of huCART-meso cells

Sponsors & Collaborators

Principal Investigators

  • Janos L. Tanyi, MD, PhD · University of Pennsylvania

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-02
Primary Completion
2038-09-30
Completion
2038-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05057715 on ClinicalTrials.gov